Analyst Research

Report Title Price
Provider: Stock Traders Daily
Provider: Thomson Reuters Stock Report
Provider: ValuEngine, Inc.
Provider: S&P Capital IQ – STARS Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Salix Pharmaceuticals Ltd Reaffirms FY 2012 Revenue Guidance; Raises FY 2012 Earnings Guidance

Wednesday, 7 Nov 2012 04:01pm EST 

Salix Pharmaceuticals Ltd reaffirmed fiscal 2012 revenue guidance of $735 Million and increases guidance for adjusted net income to $200 million or $3.13, per share, fully diluted (EPS). According to I/B/E/S Estimates, analysts are expecting the Company to report net income of $185 million and EPS of $2.91 for fiscal 2012. 

Company Quote

-2.94 -2.09%
22 Oct 2014